Published On: 12/4/2024
The Liver Meeting 2024 Research: Cirrhosis Presentation by Arun J. Sanyal, MBBS, MD
Co-chair of the TARGET-NASH steering committee, Arun J. Sanyal, MBBS, MD, helped author a new Target RWE study which was presented at AASLD 2024 titled, “A prospective assessment of the impact of decompensation of cirrhosis on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease.”
This study explores the impact of cirrhosis decompensation on patient-reported outcomes, using data from the TARGET-NASH cohort. We will discuss the changes in health-related quality of life and functional status experienced by patients as their liver disease progresses. View Dr. Sanyal's video presentation.
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
Kayla Slake
Senior Manager, Marketing
984.234.0268 ext 205
More News
-
12/04/2024
The Liver Meeting 2024 Research: Cirrhosis Presentation by Arun J. Sanyal, MBBS, MD -
12/04/2024
The Liver Meeting 2024 Research: NASH-CHECK Presentation by Arun J. Sanyal, MBBS, MD -
12/04/2024
The Liver Meeting 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR -
12/04/2024
ACG 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR -
12/04/2024
ACG 2024 Research: Presentation by Evan S. Dellon, MD, MPH